Antituberculosis-Drugs Induced DRESS: A Multidrug Hypersensitivity or Drug Hypersensitivity Relapse? A Case Report.

DRESS antituberculosis drugs desensitization hypersensitivity relapse

Journal

Hospital pharmacy
ISSN: 0018-5787
Titre abrégé: Hosp Pharm
Pays: United States
ID NLM: 0043175

Informations de publication

Date de publication:
Feb 2024
Historique:
pmc-release: 01 02 2025
medline: 15 1 2024
pubmed: 15 1 2024
entrez: 15 1 2024
Statut: ppublish

Résumé

DRESS related to first-line antituberculosis drugs (ATD) is a challenging diagnosis. With a long-lasting combined treatment of 4-concomitantly administrated drugs, identification of the culprit drug remains difficult and may expose patients to treatment interruption and affect their outcome. A 42-year-old female, treated with isoniazid, rifampicin, pyrazinamide and ethambutol for multifocal tuberculosis, developed, 40 days later, hyperthermia, facial edema, cervical lymphadenopathy and generalized exanthema. Biological test results revealed eosinophilia, atypical lymphocytes, and liver injury. DRESS was suspected, and ATD were withdrawn. As patch tests for the 4 ATD showed negative results, we decided to reintroduce pyrazinamide, ethambutol and rifampicin separately with a 3-day interval. Pyrazinamide and rifampicin were tolerated. However, after receiving ethambutol, she developed fever and generalized rash, with no biological abnormalities. Since ethambutol was claimed to be the culprit drug, isoniazid was added, and 10 hours later, the patient developed fever, facial edema, generalized rash, eosinophilia and liver injury. This clinical and biological pattern resolved 2 weeks later. This report suggests a hypersensitivity relapse to ethambutol after isoniazid-induced DRESS.

Identifiants

pubmed: 38223863
doi: 10.1177/00185787231185870
pii: 10.1177_00185787231185870
pmc: PMC10786051
doi:

Types de publication

Case Reports

Langues

eng

Pagination

10-14

Informations de copyright

© The Author(s) 2023.

Déclaration de conflit d'intérêts

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Khadija Mansour (K)

Department of Clinical Pharmacology, Fatouma Bourguiba University Hospital, Monastir, Tunisia.

Zohra Chadli (Z)

Department of Clinical Pharmacology, Fatouma Bourguiba University Hospital, Monastir, Tunisia.

Najah Ben Fadhel (N)

Department of Clinical Pharmacology, Fatouma Bourguiba University Hospital, Monastir, Tunisia.

Nadia Ben Fredj (N)

Department of Clinical Pharmacology, Fatouma Bourguiba University Hospital, Monastir, Tunisia.

Haifa Ben Romdhane (H)

Department of Clinical Pharmacology, Fatouma Bourguiba University Hospital, Monastir, Tunisia.

Amel Chaabane (A)

Department of Clinical Pharmacology, Fatouma Bourguiba University Hospital, Monastir, Tunisia.

Adnene Toumi (A)

Department of Infectious Diseases, Fattouma Bourguiba University Hospital, Monastir, Tunisia.

Karim Aouam (K)

Department of Clinical Pharmacology, Fatouma Bourguiba University Hospital, Monastir, Tunisia.

Classifications MeSH